A prospective randomised phase II trial of thalidomide with carboplatin compared with carboplatin alone as a first-line therapy in women with ovarian cancer, with evaluation of potential surrogate markers of angiogenesis.

S R Muthuramalingam(Churchill Hospital), Trivadi S. Ganesan(Churchill Hospital), Chengcheng Han(Asia Pacific Center for Theoretical Physics), S. Wilner, Jeremy Braybrooke(University Hospitals Bristol NHS Foundation Trust), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Alfred D. Jenkins, Kulbeer Kaur, Andrew D. Blann(Birmingham City Hospital), Timothy Perren(University of Leeds)
PubMed
January 1, 2011
Cited by 7

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
|The Lancet|2022|664
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|605
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
|The Lancet Oncology|2014|374
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
|The Lancet Oncology|2020|351